Mereo BioPharma Group plc – NASDAQ:MREO
Founder-led company
Mereo BioPharma Group stock price today
$1.649
-2.08
-55.8%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
Mereo BioPharma Group stock price monthly change
-10.12%
month
Mereo BioPharma Group stock price quarterly change
-10.12%
quarter
Mereo BioPharma Group stock price yearly change
+54.13%
year
Mereo BioPharma Group key metrics
Market Cap | 499.79M |
Enterprise value | 53.48M |
P/E | 10.18 |
EV/Sales | N/A |
EV/EBITDA | -8.05 |
Price/Sales | N/A |
Price/Book | 1.08 |
PEG ratio | 0.09 |
EPS | -0.05 |
Revenue | N/A |
EBITDA | -36.62M |
Income | -35.15M |
Revenue Q/Q | -100% |
Revenue Y/Y | 128.46% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMereo BioPharma Group stock price history
Mereo BioPharma Group stock forecast
Mereo BioPharma Group financial statements
| Jun 2023 | 8.79M | -13.60M | -154.74% |
|---|---|---|---|
| Sep 2023 | 533.42K | -6.55M | -1229.72% |
| Dec 2023 | 361.1K | -6.04M | -1674.49% |
| Mar 2024 | 0 | -8.95M |
| Dec 2023 | 361.1K | -6.04M | -1674.49% |
|---|---|---|---|
| Mar 2024 | 0 | -8.95M | |
| Oct 2025 | 0 | -6.89M | |
| Dec 2025 | 0 | -8.27M |
Analysts Price target
Financials & Ratios estimates
| 2024-05-15 | -0.02 | -0.01 |
|---|
| Jun 2023 | 80638000 | 22.89M | 28.39% |
|---|---|---|---|
| Sep 2023 | 54506570 | 13.08M | 24% |
| Dec 2023 | 66499000 | 15.96M | 24% |
| Mar 2024 | 55937000 | 13.09M | 23.42% |
| Jun 2023 | -16.72M | -415.58K | -178.81K |
|---|---|---|---|
| Sep 2023 | -2.47M | -289.43K | 4.54M |
| Dec 2023 | -2.11M | -292.93K | 4.56M |
| Mar 2024 | -7.98M | -699.6K | 0 |
Mereo BioPharma Group alternative data
| Aug 2023 | 36 |
|---|---|
| Sep 2023 | 36 |
| Oct 2023 | 36 |
| Nov 2023 | 36 |
| Dec 2023 | 36 |
| Jan 2024 | 36 |
| Feb 2024 | 36 |
| Mar 2024 | 36 |
| Apr 2024 | 36 |
| May 2024 | 33 |
| Jun 2024 | 33 |
| Jul 2024 | 33 |
Mereo BioPharma Group other data
4.01%
-6.54%
of MREO is owned by hedge funds
31
-28
24.19M
-37.38M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 0 | 100432 |
| Insider | Compensation |
|---|---|
| Dr. Denise Scots-Knight Ph.D. (1959) Co-Founder, Chief Executive Officer & Executive Director | $1,170,000 |
Mr. Charles Sermon (1969) Co-Founder, Gen. Counsel & Company Sec. | $855,930 |
Dr. Alastair MacKinnon M.D., MBBS (1970) Co-Founder and Chief of Portfolio & Pipeline Strategy | $843,430 |
Dr. John P. Richard M.B.A., MBA (1957) Co-Founder & Chief Bus. Officer | $799,480 |
| Dr. John A. Lewicki Ph.D. (1952) Chief Scientific Officer | $756,020 |
Ms. Alexandra Hughes-Wilson (1971) Chief of Patient Access & Commercial Planning | $484,370 |
-
What's the price of Mereo BioPharma Group stock today?
One share of Mereo BioPharma Group stock can currently be purchased for approximately $1.65.
-
When is Mereo BioPharma Group's next earnings date?
Unfortunately, Mereo BioPharma Group's (MREO) next earnings date is currently unknown.
-
Does Mereo BioPharma Group pay dividends?
No, Mereo BioPharma Group does not pay dividends.
-
How much money does Mereo BioPharma Group make?
Mereo BioPharma Group has a market capitalization of 499.79M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 563.57% to 10M US dollars. Mereo BioPharma Group made a loss 29.47M US dollars in net income (profit) last year or -$0.01 on an earnings per share basis.
-
What is Mereo BioPharma Group's stock symbol?
Mereo BioPharma Group plc is traded on the NASDAQ under the ticker symbol "MREO".
-
What is Mereo BioPharma Group's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Mereo BioPharma Group?
Shares of Mereo BioPharma Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Mereo BioPharma Group's key executives?
Mereo BioPharma Group's management team includes the following people:
- Dr. Denise Scots-Knight Ph.D. Co-Founder, Chief Executive Officer & Executive Director(age: 66, pay: $1,170,000)
- Mr. Charles Sermon Co-Founder, Gen. Counsel & Company Sec.(age: 56, pay: $855,930)
- Dr. Alastair MacKinnon M.D., MBBS Co-Founder and Chief of Portfolio & Pipeline Strategy(age: 55, pay: $843,430)
- Dr. John P. Richard M.B.A., MBA Co-Founder & Chief Bus. Officer(age: 68, pay: $799,480)
- Dr. John A. Lewicki Ph.D. Chief Scientific Officer(age: 73, pay: $756,020)
- Ms. Alexandra Hughes-Wilson Chief of Patient Access & Commercial Planning(age: 54, pay: $484,370)
-
Is Mereo BioPharma Group founder-led company?
Yes, Mereo BioPharma Group is a company led by its founders Dr. Denise Scots-Knight Ph.D., Mr. Charles Sermon, Dr. Alastair MacKinnon M.D., MBBS and Dr. John P. Richard M.B.A., MBA.
-
How many employees does Mereo BioPharma Group have?
As Jul 2024, Mereo BioPharma Group employs 33 workers, which is 8% less then previous quarter.
-
When Mereo BioPharma Group went public?
Mereo BioPharma Group plc is publicly traded company for more then 6 years since IPO on 24 Apr 2019.
-
What is Mereo BioPharma Group's official website?
The official website for Mereo BioPharma Group is mereobiopharma.com.
-
How can i contact Mereo BioPharma Group?
Mereo BioPharma Group can be reached via phone at +44 333 023 7300.
Mereo BioPharma Group company profile:
Mereo BioPharma Group plc
mereobiopharma.comExchange:
NASDAQ
Full time employees:
33
Industry:
Biotechnology
Sector:
Healthcare
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
One Cavendish Place
London, W1G 0QF
London, W1G 0QF
CIK: 0001719714
ISIN: US5894921072
CUSIP: 589492107
